Biotech RadarJobs updated

COMPANY

Cartesian Therapeutics Inc.

HQ: Frederick, MD source · cartesiantherapeutics.com ↗ · Mid-Atlantic

Clinical Phase 3

Keywords: cell therapy mRNA immunology autoimmune diseases Multiple Myeloma Myasthaenia Gravis Antisynthetase Syndrome Generalized Myasthenia Gravis Childhood-onset Systemic Lupus Erythematous ANCA-Associated Vasculitis Juvenile Myasthenia Gravis Juvenile Dermatomyositis Systemic Lupus Erythematosus Refractory Multiple Myeloma Relapsed Multiple Myeloma Relapse Multiple Myeloma Acute Respiratory Distress Syndrome Covid19 Myeloma Multiple Descartes-08 Decartes-08 Descartes-15 Descartes 11 Descartes-25 Descartes 30

Location: Frederick, MD · source · Oct 15, 2026

Profile checked Oct 10, 2026

12Trials (company is sponsor)

Timeline

  1. Debt Debt financing: $150M (up to, as announced), announced May 26, 2026. Source: company release on GlobeNewswire. source ↗
  2. Trial start Phase 2: Descartes-08 in Autoantibody Myositis source ↗
  3. Trial start Phase 1/Phase 2: Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders source ↗
  4. Grant Government grant — SBIR: $1.5M (annual award, as published), announced May 20, 2025. Agency: NIH/NINDS. Source: government award database. source ↗
  5. Trial start Phase 3: Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis source ↗
  6. Trial start Phase 1: Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma source ↗
  7. Trial start Phase 2: Descartes-08 for Patients With Systemic Lupus Erythematosus source ↗
  8. Trial start Phase 2: Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy source ↗
  9. Trial start Phase 1: Descartes-25 in Relapsed/Refractory Multiple Myeloma source ↗
  10. Trial start Phase 2: Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy source ↗
  11. Trial start Phase 1: Study of Descartes-30 in Acute Respiratory Distress Syndrome source ↗
  12. Trial start Phase 2: Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) source ↗
  13. Trial start Phase 1: Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma source ↗
  14. Trial start Phase 1: Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Debt: $150.0M. Last 2 years.

Clinical trials (lead sponsor) 12

RecordTitlePhaseStatusStartPrimary completion
NCT06799247Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia GravisPhase 3Active, not recruitingMay 6, 2025Dec 30, 2026 (estimated)
NCT07391605Descartes-08 in Autoantibody MyositisPhase 2RecruitingApr 28, 20262027-11 (estimated)
NCT04146051Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)Phase 2Active, not recruitingDec 4, 2019Jan 5, 2026 (actual)
NCT07089121Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune DisordersPhase 1/Phase 2RecruitingJan 14, 20262027-12 (estimated)
NCT06038474Descartes-08 for Patients With Systemic Lupus ErythematosusPhase 2Active, not recruitingFeb 12, 2024Dec 1, 2026 (estimated)
NCT06304636Descartes-15 for Patients With Relapsed/Refractory Multiple MyelomaPhase 1TerminatedJun 19, 2024Apr 14, 2025 (actual)
NCT03994705Descartes-11 in Patients With Relapsed/Refractory Multiple MyelomaPhase 1TerminatedAug 1, 2019May 27, 2021 (actual)
NCT04436029Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction TherapyPhase 2CompletedFeb 24, 2021Feb 18, 2022 (actual)
NCT05113342Descartes-25 in Relapsed/Refractory Multiple MyelomaPhase 1TerminatedNov 25, 2021May 9, 2023 (actual)
NCT04524962Study of Descartes-30 in Acute Respiratory Distress SyndromePhase 1TerminatedFeb 23, 2021Sep 9, 2022 (actual)
NCT04816526Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction TherapyPhase 2TerminatedDec 1, 2021Aug 4, 2022 (actual)
NCT03448978Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With MyelomaPhase 1TerminatedMar 8, 2018Apr 19, 2021 (actual)
Feedback